ARCII: A Phase II trial of the HIV protease inhibitor Nelfinavir
in combination with chemoradiation for locally advanced inoperable
pancreatic cancer

ARCII: A Phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer

Background and purpose Nelfinavir can enhance intrinsic radiosensitivity, reduce hypoxia and improve vascularity. We conducted a phase II trial combining nelfinavir with chemoradiotherapy (CRT) for locally advanced inoperable pancreatic cancer (LAPC). Materials and methods Radiotherapy (50.4 Gy/28...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, J, Fokas, E, Dutton, S, Hawkins, M, al., E
Formato:	Journal article
Publicado:	Elsevier 2016

Ejemplares similares

ARCII: Nelfinavir, a hypoxia-modifying agent, in combination with chemoradiotherapy (CRT) in locally-advanced pancreatic cancer (LAPC)–mechanism and clinical outcomes
por: Wilson, J, et al.
Publicado: (2017)

A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
por: Brunner, T, et al.
Publicado: (2008)

A phase I-trial of the HIV protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer
por: Brunner, T, et al.
Publicado: (2008)

Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
por: Brunner, T, et al.
Publicado: (2008)

HIV-1 genotypes related to failure of nelfinavir as the first protease inhibitor treatment
por: Unaí Tupinambás, et al.

New insights into the in silico prediction of HIV protease resistance to nelfinavir.
por: Dinler A Antunes, et al.
Publicado: (2014-01-01)

Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir
por: Chao Ying, et al.
Publicado: (2008-02-01)

Dosimetric parameters predict toxicity in chemoradiotherapy with nelfinavir for pancreatic cancer
por: Holyoake, D, et al.
Publicado: (2016)

Definitive chemoradiation in patients with inoperable oesophageal carcinoma.
por: Crosby, T, et al.
Publicado: (2004)

The HIV Protease Inhibitor Nelfinavir Downregulates Akt Phosphorylation by Inhibiting Proteasomal Activity and Inducing the Unfolded Protein Response
por: Anjali K. Gupta, et al.
Publicado: (2007-04-01)

Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes.
por: Pranav Kumar, et al.
Publicado: (2010-03-01)

Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: the phase 1/randomised phase 2 SCALOP-2 trial
por: Mukherjee, S, et al.
Publicado: (2024)

HIV protease inhibitor nelfinavir is a potent drug candidate against echinococcosis by targeting Ddi1-like protein
por: Zhongli Liu, et al.
Publicado: (2022-08-01)

Pneumocephalus after the Treatment of an Inoperable Superior Sulcus Tumor with Chemoradiation
por: Ashley Albert, et al.
Publicado: (2017-01-01)

The impact of the nelfinavir resistance-conferring mutation D30N on the susceptibility of HIV-1 subtype B to other protease inhibitors
por: André FA Santos, et al.
Publicado: (2011-03-01)

SCALOP-2: A randomised trial of induction GEMABX followed by chemoradiation (high/standard dose radiation) +/-nelfinavir for locally advanced pancreatic cancer: results of the dose-finding component
por: Mukherjee, S, et al.
Publicado: (2018)

The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells
por: Al-Assar, O, et al.
Publicado: (2016)

Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial
por: Sudeep Gupta, et al.
Publicado: (2022-04-01)

ATR targeting by the novel inhibitor VE-822 selectively sensitizes pancreatic cancer cells and tumors to radiation and chemoradiation
por: Fokas, E, et al.
Publicado: (2013)

The HIV protease and PI3K/Akt inhibitor nelfinavir does not improve the curative effect of fractionated irradiation in PC-3 prostate cancer in vitro and in vivo
por: Steffi Liebscher, et al.
Publicado: (2017-02-01)

THE ROLE OF RADIOTHERAPY DELAY IN THE CHEMORADIATION TREATMENT FOR STAGE III INOPERABLE NON-SMALL CELL LUNG CANCER
por: E. P. Solov’eva, et al.
Publicado: (2016-02-01)

Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08)
por: Christoph Driessen, et al.
Publicado: (2016-03-01)

The efficacy of nelfinavir and lopinavir/ritonavir in the treatment of HIV-infected pediatric patients
por: V. B. Denisenko,, et al.
Publicado: (2018-12-01)

Chemoradiation of pancreatic carcinoma
por: Erdinç Nayır, et al.
Publicado: (2016-08-01)

Nelfinavir and Non-Nucleoside Reverse Transcriptase Inhibitor-Based Salvage Regimes in Heavily Hiv Pretreated Patients
por: Jean-Guy Baril, et al.
Publicado: (2003-01-01)

The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo
por: Camille Bono, et al.
Publicado: (2012-07-01)

Survival and Toxicity in Patients With Unresectable or Inoperable Biliary Tract Cancers With Ablative Radiation Therapy Versus Nonablative Chemoradiation
por: Hilario Yankey, MD, MBA, et al.
Publicado: (2024-04-01)

Combination of chemoradiation therapy with immunotherapy in the treatment of patients with inoperable stage III non-small cell lung cancer
por: N. V. Marinichenko, et al.
Publicado: (2020-12-01)

Spectrophometric Determination of Nelfinavir Mesylate
por: K. Vanitha Prakash, et al.
Publicado: (2006-01-01)

The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study
por: Alison K. Yoder, et al.
Publicado: (2021-07-01)

ACCELEREATED HYPERFRACTIONATED WITH UNEVEN CRUSHING DAILY DOSE WITH CHEMORADIATION TREATMENT OF INOPERABLE NON-SMALL CELL LUNG CANCER.
por: D. V. Gogolin, et al.
Publicado: (2016-02-01)

Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children
por: Léon Juan, et al.
Publicado: (2006-07-01)

Induction of Suicidal Erythrocyte Death by Nelfinavir
por: Rosi Bissinger, et al.
Publicado: (2015-05-01)

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma
por: Lenka Besse, et al.
Publicado: (2023-03-01)

Nelfinavir: An Old Ally in the COVID-19 Fight?
por: Anna Gidari, et al.
Publicado: (2022-12-01)

Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells
por: Serena Veschi, et al.
Publicado: (2018-09-01)

Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer
por: Kang Young-Nam, et al.
Publicado: (2010-06-01)

Clinical trial of oral nelfinavir before and during radiation therapy for advanced rectal cancer
por: Hill, E, et al.
Publicado: (2016)

Downstaging of pancreatic carcinoma after neoadjuvant chemoradiation.
por: Tinkl, D, et al.
Publicado: (2009)

Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape
por: Camacho Ricardo J, et al.
Publicado: (2010-08-01)